

# Antidepressants Information

## Introduction

There has been extensive research into antidepressants over several decades, and our understanding of how these medications work — and how helpful they are on average — has continued to evolve. Some of the findings from this research are not widely discussed in routine clinical practice.

As a prescribing clinician, I believe it is important that people are given clear, balanced information about antidepressants, including what is known, what remains uncertain, and the range of possible benefits and harms. This is especially important when decisions may involve long-term treatment or difficult trade-offs.

In everyday primary care, consultations are often short, and it is not always possible to explore this information in sufficient depth during an appointment. This document was developed to support discussions that have already taken place, allowing people to reflect on the information in their own time and return to it if helpful.

The content is based on my own appraisal of the research literature, informed by clinical experience and ongoing review of the evidence. Other clinicians may interpret parts of this evidence differently, and reasonable professionals can reach different conclusions.

Research studies describe average effects across large groups of people. Individual responses vary widely. Some people find antidepressants very helpful with few side effects, others experience limited benefit or unwanted effects, and many fall somewhere in between. There is currently no reliable way to predict in advance how any one individual will respond.

This document is intended to support informed, shared decision-making, rather than to direct or discourage any particular choice. Decisions about treatment should always take place in discussion with a clinician, taking into account the individual's situation, values, and preferences

## How Do Antidepressants Work?

For many years, depression has commonly been explained as being caused by a chemical imbalance in the brain, usually described as a deficiency of serotonin. This explanation has become widespread in both clinical practice and public understanding.

However, decades of research have not found consistent evidence that depression is caused by a deficiency of serotonin or by a simple chemical imbalance in the brain. Studies examining serotonin levels, receptor activity, and genetic markers have not shown a clear or reliable pattern that would support this explanation as it is commonly presented.

Antidepressants do affect brain chemistry. Most commonly, they alter serotonin or noradrenaline signalling by changing how these chemicals are reabsorbed or processed in the brain. These effects occur in anyone taking the medication, regardless of whether they are experiencing depression.

Rather than correcting a known underlying abnormality, current evidence suggests it is more accurate to understand antidepressants as creating an altered brain state. This altered state can be experienced as helpful for some people at some points in their lives, while for others it may be unhelpful or associated with unwanted effects.

How these chemical changes lead to improvements in mood or functioning is not fully understood. One proposed mechanism is that some antidepressants reduce REM (dream) sleep and increase more restorative stages of sleep, which may help shift one of the physiological patterns often seen in depression. Other mechanisms are likely involved, and no single explanation fully accounts for the range of effects observed.

It is important to emphasise that people respond very differently. Some experience meaningful benefit, others little change, and some experience adverse effects. There is currently no reliable way to predict an individual's response in advance.

Different clinicians and researchers place different emphasis on how antidepressants should be understood. Some continue to use disease-based explanations, while others favour a drug-centred model, which focuses on the direct effects of medications on brain function and experience. Understanding these differences can help people make more informed decisions about treatment.

Some people find biological explanations helpful in making sense of their experience, while others prefer explanations that focus more on life context, stress, trauma, or meaning. There is no single "correct" way to understand depression or its treatment, and people are entitled to arrive at the understanding that best fits their experience and values.

## **Are Antidepressants Effective?**

In short-term clinical trials, many people report some improvement after starting an antidepressant. On average, antidepressants perform better than placebo in these trials, but the size of the difference is modest and varies widely between individuals.

It is important to understand how effectiveness is measured in research. Most antidepressant trials use symptom rating scales, such as the Hamilton Depression Rating Scale (HAM-D). Changes on these scales do not always translate into noticeable improvements in day-to-day functioning or quality of life, and different thresholds are used to define outcomes such as "response" or "remission".

Across large meta-analyses, the average difference between antidepressants and placebo on symptom rating scales is small. For many people, this difference is below the level that would be expected to produce a clearly noticeable change in everyday life. This does not mean that no one benefits; rather, it reflects that average effects across large groups are limited, even though some individuals experience meaningful improvement.

Severity appears to matter. In people with very severe depression, drug–placebo differences are somewhat larger on average. However, this group represents a minority of participants in most trials, and even in severe depression the average benefit remains modest. Some analyses suggest that part of the apparent increase in drug–placebo difference at higher severity may reflect reduced placebo responsiveness rather than a large increase in medication effect.

A substantial proportion of improvement seen in antidepressant trials occurs in the placebo arm. This reflects the powerful effects of expectation, therapeutic contact, and natural change over time. Placebo responses are associated with real, measurable changes in brain networks involved in mood, motivation, and emotional regulation. The presence of a strong placebo response does not mean antidepressants never help, but it does place their average effects in context.

Longer-term and real-world outcomes are more difficult to assess. Many clinical trials last only a few weeks, whereas people often take antidepressants for much longer. Studies conducted in routine clinical settings show mixed outcomes: some people achieve remission, some experience partial benefit, and others discontinue treatment because of limited benefit or side effects. The proportion of people who experience sustained remission while remaining on long-term antidepressant treatment appears to be relatively limited.

Because of withdrawal effects and physiological dependence on the medication over time, starting an antidepressant can complicate and sometimes prolong recovery for some people, rather than shorten it, particularly when compared with the natural improvement seen in many depressive episodes over time without medication. Repeated medication changes or combinations commonly produce diminishing returns for many people.

Overall, the evidence suggests that antidepressants can be helpful for some people, particularly in more severe or persistent depression, but they are not reliably or dramatically effective on average. For many individuals, potential benefits need to be weighed carefully against possible side effects, withdrawal difficulties, and alternative or additional approaches such as psychological therapy, social support, and addressing ongoing life stressors.

These findings highlight the importance of shared decision-making. Whether trying an antidepressant is reasonable depends on the individual's circumstances, severity of symptoms, previous responses, preferences, and tolerance of risk. There is no single answer that applies to everyone.

## Potential Side Effects, Dependence, and Withdrawal

Antidepressants can cause a range of physical and emotional effects. Some people experience few or no side effects, while others find them distressing or limiting. Side effects vary between individuals, between different medications, and at different stages of treatment.

### Physical and Emotional Effects

Common physical side effects include nausea, headaches, changes in sleep, gastrointestinal disturbance, sweating, and changes in appetite. These effects are often most noticeable in the early weeks of treatment and may lessen with time, but for some people they persist.

Emotional and psychological effects are also commonly reported, though they are discussed less often. Many people describe a reduction in emotional intensity, sometimes referred to as emotional blunting or numbing. This can include reduced experience of both negative and positive emotions, a sense of detachment, or feeling less connected to oneself or others.

Some people find this effect helpful for a period, particularly if emotions feel overwhelming. Others experience it as a loss of vitality, reduced enjoyment, or a change in how they relate to people and situations. These effects reflect the way antidepressants alter brain signalling and emotional processing, rather than being signs of underlying damage.

### Suicidal Thoughts and Behaviour

In all age groups, antidepressants can sometimes be associated with an increase in suicidal thoughts or behaviours, particularly in the early stages of treatment or after dose changes. This risk is highest in children, adolescents, and young adults, but careful monitoring is important for everyone.

For many adults, overall suicide risk may reduce over time if symptoms improve, but this does not remove the need for vigilance. Anyone who experiences new or worsening suicidal thoughts after starting or changing antidepressant treatment should seek medical advice promptly.

### Akathisia (Severe Inner Restlessness)

Some antidepressants can cause a condition known as akathisia. This is uncommon and involves an intense sense of inner restlessness or agitation, often accompanied by an urge to move, pace, or fidget. People may describe feeling extremely uncomfortable, driven, or unable to settle, sometimes alongside anxiety or irritability.

Akathisia is not simply anxiety and does not reflect a worsening of depression. It is a recognised drug effect that can occur particularly soon after starting an antidepressant, increasing the dose, or switching medications, though it can also occur later in treatment.

When severe, akathisia can be profoundly distressing and has been associated with an increased risk of suicidal thoughts or behaviour. Because the experience can be difficult to describe, it may be misinterpreted as agitation, anxiety, or relapse unless it is specifically considered.

Anyone who develops sudden or intense restlessness, agitation, or a sense of being unable to stay still after starting or changing antidepressant treatment should seek medical advice promptly. Early recognition and adjustment of treatment can reduce harm.

### **Dependence and Withdrawal**

When antidepressants are taken over time, the brain adapts to their presence. As a result, reducing or stopping the medication can lead to withdrawal symptoms in some people. These symptoms are common and can occur even when medication is reduced gradually.

Withdrawal symptoms vary widely and may include anxiety, low mood, irritability, sleep disturbance, dizziness, sensory disturbances (such as “electric shock” sensations), flu-like symptoms, and emotional instability. In most cases, symptoms are temporary, but for some people they can be prolonged and distressing.

Withdrawal symptoms do not necessarily mean that antidepressants cause addiction in the same way as substances such as alcohol or opioids. Antidepressants do not typically produce intoxication, craving, or compulsive dose escalation. However, the body and brain can become physiologically adapted to them over time, and many people experience withdrawal symptoms when reducing or stopping. Some people also experience a form of psychological dependence, in the sense of feeling reliant on the medication or anxious about stopping because symptoms may return or withdrawal may occur.

Gradual, individualised dose reduction under medical supervision can reduce the risk and severity of withdrawal, but cannot always prevent it entirely. This often needs to take place over many months, with increasingly small dose reductions as the dose approaches zero.

Understanding that antidepressants are not correcting a known chemical imbalance, but instead change how brain systems work while they are taken, can sometimes help people feel less fearful about reducing or stopping medication.

### **Withdrawal and Relapse — An Important Distinction**

Withdrawal symptoms are sometimes mistaken for a return or worsening of the original condition. This can happen because withdrawal effects may include low mood, anxiety, sleep disturbance, irritability, or emotional instability — symptoms that overlap with depression or anxiety.

However, these experiences do not necessarily indicate a recurrence of an underlying illness. In many cases, they reflect the brain and nervous system readjusting after long-term exposure to medication. Distinguishing between withdrawal effects and relapse can be difficult and often requires careful assessment over time.

Misinterpreting withdrawal symptoms as relapse may lead to the assumption that long-term or indefinite medication is required. For this reason, gradual dose reduction, close follow-up, and open discussion about possible withdrawal effects are important when considering stopping or reducing antidepressants.

### **Long-Term Use and Ongoing Effects**

Many people take antidepressants for months or years. Long-term use may be appropriate for some, particularly when benefits are clear and outweigh harms. For others, continued use may bring diminishing benefit, ongoing side effects, or increasing difficulty stopping.

At present, there is limited high-quality evidence about the long-term effects of antidepressant use beyond a few years. This uncertainty makes regular review important, including discussion of ongoing benefit, side effects, and whether continuing treatment still feels right for the individual.

### **Putting Risks and Benefits in Context**

Antidepressants can be helpful and, in some cases, life-saving. At the same time, they carry real risks and uncertainties. Neither benefit nor harm is guaranteed, and individual experiences vary greatly.

Understanding possible side effects, emotional changes, akathisia, and withdrawal effects allows people to make informed choices about starting, continuing, or stopping treatment. These discussions are most effective when they take place over time, within a trusting clinical relationship, and are revisited as circumstances change.

Decisions about treatment are most effective when they take account of the individual's circumstances, preferences, previous experiences, and tolerance of risk, and when they are reviewed over time.

## **Conclusion**

Antidepressants are widely used and can be helpful for some people, particularly when symptoms are severe or persistent. At the same time, they are not a universal solution and their effects vary greatly between individuals.

Understanding what antidepressants are known to do, what remains uncertain, and what potential benefits and harms may arise allows people to make informed choices that align with their values and circumstances. There is no single "right" decision that applies to everyone.

Decisions about starting, continuing, or stopping antidepressants are best made through shared decision-making, within an ongoing clinical relationship, and revisited as situations and needs change.

## References and further reading

National Institute for Health and Care Excellence (NICE).

*Depression in adults: treatment and management*. NICE guideline NG222. 2022.

Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT.

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration.

*PLoS Medicine*. 2008;5(2):e45.

Cipriani A, Furukawa TA, Salanti G, et al.

Comparative efficacy and acceptability of antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.

*The Lancet*. 2018;391(10128):1357–1366.

Lewis G, Duffy L, Ades A, et al.

The clinical effectiveness of sertraline in primary care (PANDA): a pragmatic randomised controlled trial.

*The Lancet Psychiatry*. 2019;6(11):903–914.

Moncrieff J.

*The Myth of the Chemical Cure: A Critique of Psychiatric Drug Treatment*.

Basingstoke: Palgrave Macmillan; 2008.

Benedetti F.

*Placebo Effects: Understanding the Mechanisms in Health and Disease*.

Oxford: Oxford University Press; 2008.

Horowitz MA, Taylor D.

Tapering of SSRI treatment to mitigate withdrawal symptoms.

*The Lancet Psychiatry*. 2019;6(6):538–546.

Davies J, Read J.

A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based?

*Addictive Behaviors*. 2019;97:111–121.

Food and Drug Administration (FDA).

*Antidepressant use in children, adolescents and adults: suicidality and risk warnings*. U.S.

Food and Drug Administration. 2007